DRREDDY Dr Reddy's Laboratories Ltd Company Mergers Announcement 2025 - Licensing Agreement Dr. Reddy's Laboratories has entered into a licensing agreement with Shanghai Henlius Biotech to exclusively commercialize the biosimilar Daratumumab in the US and Europe, paying up to $131.6 million including $33 million upfront and milestone payments..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Dr Reddy's Laboratories Ltd